Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07089888 · ClinicalTrials.gov registry record · Phase 3
A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
A Phase 3 study of Tophaceous Gout, sponsored by Crystalys Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 250
- Enrollment target
- 20
- Study locations
NCT07089888: Recruiting Phase 3 study of Tophaceous Gout, sponsored by Crystalys Therapeutics.
NCT07089888 is a Phase 3 study of Tophaceous Gout that is actively recruiting participants, run by Crystalys Therapeutics. The registered enrollment target is 250 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (68% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07089888, a Phase 3 study of Tophaceous Gout, is actively recruiting participants, sponsored by Crystalys Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 250 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol in adult participants with tophaceous gout.
Conditions Studied
Interventions
- DRUG Allopurinol
- DRUG Dotinurad
Study Locations (20)
California
- Medvin Clinical Research - Covina - Covina
- West Coast Research - Dublin
- Infinity Clinical Research - Norco
- Amicis Research Center - Balboa - Northridge
- Dream Team Clinical Research - Pomona
- Acclaim Clinical Research, Inc. - San Diego
- East Bay Rheumatology Medical Group - San Leandro
- BTC Network - Encompass Clinical Research - Spring Valley
- Cohen Medical Centers - Thousand Oaks
- Medvin Clinical Research - Tujunga - Tujunga
Arizona
- Arizona Arthritis & Rheumatology Associates (AARA) - Gilbert - Gilbert
- Arizona Arthritis & Rheumatology Associates (AARA) - Glendale - Glendale
- Arizona Arthritis & Rheumatology Associates (AARA) - Mesa - Mesa
- Del Sol Research Management - Tucson East - Tucson
Florida
- Bradenton Research Center - Bradenton
- Herco Medical and Research Center, Inc - Coral Gables
- New Generation of Medical Research - Hialeah
Alabama
- Alabama Clinical Therapeutics - Birmingham
- G & L Research - Foley
Colorado
- Denver Arthritis Clinic - Lowry - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2025-08-04 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 3 |
What NCT07089888 shows while recruiting
NCT07089888 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Tophaceous Gout appearing as the primary indexed condition, and to 2 interventions - of which Allopurinol is the first listed.
NCT07089888 names 20 study sites across 5 states, led by California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT07089888 about?
NCT07089888 is a clinical study titled "A Study of Dotinurad Versus Allopurinol in Tophaceous Gout". The primary objective of this study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol in adult participants with tophaceous gout.
What is the current status of trial NCT07089888?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2025-08-04. Estimated completion is 2027-12-31.
What conditions does trial NCT07089888 study?
This clinical trial studies the following conditions: Tophaceous Gout.
What interventions are being tested in trial NCT07089888?
The interventions under investigation include: Allopurinol (DRUG), Dotinurad (DRUG).
Who is sponsoring clinical trial NCT07089888?
This trial is sponsored by Crystalys Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07089888 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tophaceous Gout
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07089888's enrollment target sits among peer trials
250 1250th of 2000 higher than 735 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI